Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications | Zendy

Pouran Layegh | Zendy; Zahra Khademi | Zendy; Monnavar Afzal Aghaee | Zendy; Toktam Moghiman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications

Author(s) -

Pouran Layegh,

Zahra Khademi,

Monnavar Afzal Aghaee,

Toktam Moghiman

Publication year - 2014

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/piu021

Subject(s) - meglumine antimoniate , medicine , cutaneous leishmaniasis , leishmaniasis , dermatology , adverse effect , clinical trial , antiparasitic agent , meglumine , leishmania , leishmania infantum , pharmacology , immunology , visceral leishmaniasis , magnetic resonance imaging , radiology , parasite hosting , world wide web , computer science

Children account for 7%-20% of cutaneous leishmaniasis cases in Iran, but there are few safety data to guide pediatric antiparasitic therapy. We evaluated the clinical and laboratory tolerance of the systemic pentavalent antimonial compound meglumine antimoniate, in 70 Iranian children with cutaneous leishmaniasis. Adverse effects were similar to those seen in adults.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research